ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

avacincaptad pegol

Also written as “Avacincaptad Pegol”, “Izervay™” and “Zimura”.

Its studies are mostly in Geographic Atrophy · Macular Degeneration · Polypoidal Choroidal Vasculopathy · Stargardt Disease, led by 2 companies.

Drug pageAvacincaptad pegol: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 6, 202511 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharmaits history only101 open or runningphase 4since May 6, 2025Jul 1, 2008Jun 30, 2027phase 4 · NCT06970665
Hoffmann-La Roche10 open or runningphase 1since Apr 29, 2025Apr 29, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named avacincaptad pegolINNProposed as its International Nonproprietary Name in WHO's List 113
  2. Apr 29, 2025First study: phase 1 study in Geographic AtrophyFirst studyNCT06961370 · 27 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06961370Geographic Atrophy · United States1TerminatedFeb 3, 202627

How it is read

Names in the registry

  • “Avacincaptad Pegol”, 6 entries
  • “avacincaptad pegol”, 3 entries
  • “Izervay™”, 1 entry
  • “Zimura”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.